Harborside


Avicanna Inc.

TSE: AVCN


Canadian symbol: AVCN.TO
US symbol: AVCNF

Currency in CAD

Valuation Measures4

Market Cap (intraday) N/A
Enterprise Value N/A
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)N/A
Price/Book (mrq)N/A
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA N/A

Trading Information

Stock Price History

Beta (5Y Monthly) 2.18
52-Week Change 3N/A
S&P500 52-Week Change 3N/A
52 Week High 31.0800
52 Week Low 30.1600
50-Day Moving Average 30.3004
200-Day Moving Average 30.5603

Share Statistics

Avg Vol (3 month) 356.11k
Avg Vol (10 day) 366.48k
Shares Outstanding 545.86M
Implied Shares Outstanding 6N/A
Float 841.48M
% Held by Insiders 123.93%
% Held by Institutions 10.00%
Shares Short (Apr 28, 2022) 415.31k
Short Ratio (Apr 28, 2022) 40.23
Short % of Float (Apr 28, 2022) 4N/A
Short % of Shares Outstanding (Apr 28, 2022) 40.03%
Shares Short (prior month Mar 30, 2022) 418.99k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2021
Most Recent Quarter (mrq)Dec 30, 2021

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-349.15%

Management Effectiveness

Return on Assets (ttm)-27.20%
Return on Equity (ttm)-161.15%

Income Statement

Revenue (ttm)3.27M
Revenue Per Share (ttm)0.08
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)2.83M
EBITDA -10.85M
Net Income Avi to Common (ttm)-16.77M
Diluted EPS (ttm)-0.6060
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)31k
Total Cash Per Share (mrq)0
Total Debt (mrq)1.66M
Total Debt/Equity (mrq)24.06
Current Ratio (mrq)0.60
Book Value Per Share (mrq)0.09

Cash Flow Statement

Operating Cash Flow (ttm)-11.66M
Levered Free Cash Flow (ttm)-9.34M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.




Company News Date
AVCN.TO
Avicanna
2 days ago
AVCN.TO
Avicanna
2 weeks ago
AVCN.TO
Avicanna
1 month ago
AVCN.TO
Avicanna
2 months ago
AVCN.TO
Avicanna
2 months ago
AVCN.TO
Avicanna
4 months ago
AVCN.TO
Avicanna
4 months ago
AVCN.TO
Avicanna
4 months ago
AVCN.TO
Avicanna
4 months ago
AVCN.TO
Avicanna
5 months ago
AVCN.TO
Avicanna
5 months ago
AVCN.TO
Avicanna
5 months ago
AVCN.TO
Avicanna
5 months ago
AVCN.TO
Avicanna
6 months ago
AVCN.TO
Avicanna
6 months ago
AVCN.TO
Avicanna
6 months ago
AVCN.TO
Avicanna
6 months ago
AVCN.TO
Avicanna
6 months ago
AVCN.TO
Avicanna
6 months ago
AVCN.TO
Avicanna
7 months ago
AVCN.TO
Avicanna
7 months ago
AVCN.TO
Avicanna
7 months ago
AVCN.TO
Avicanna
7 months ago
AVCN.TO
Avicanna
7 months ago
AVCN.TO
Avicanna
8 months ago
AVCN.TO
Avicanna
8 months ago
AVCN.TO
Avicanna
9 months ago
AVCN.TO
Avicanna
9 months ago
AVCN.TO
Avicanna
10 months ago
AVCN.TO
Avicanna
10 months ago
AVCN.TO
Avicanna
10 months ago
AVCN.TO
Avicanna
10 months ago
AVCN.TO
Avicanna
1 year ago
AVCN.TO
Avicanna
1 year ago
AVCN.TO
Avicanna
1 year ago
AVCN.TO
Avicanna
1 year ago
AVCN.TO
Avicanna
1 year ago
AVCN.TO
Avicanna
1 year ago
AVCN.TO
Avicanna
1 year ago
AVCN.TO
Avicanna
1 year ago
AVCN.TO
Avicanna
1 year ago
AVCN.TO
Avicanna
1 year ago
AVCN.TO
Avicanna
1 year ago
AVCN.TO
Avicanna
1 year ago
AVCN.TO
Avicanna
1 year ago
AVCN.TO
Avicanna
1 year ago
AVCN.TO
Avicanna
1 year ago
AVCN.TO
Avicanna
2 years ago
AVCN.TO
Avicanna
2 years ago
AVCN.TO
Avicanna
2 years ago
AVCN.TO
Avicanna
2 years ago
AVCN.TO
Avicanna
2 years ago
AVCN.TO
Avicanna
2 years ago
AVCN.TO
Avicanna
2 years ago
AVCN.TO
Avicanna
2 years ago
AVCN.TO
Avicanna
2 years ago
AVCN.TO
Avicanna
2 years ago
AVCN.TO
Avicanna
2 years ago
AVCN.TO
Avicanna
2 years ago
AVCN.TO
Avicanna
2 years ago
AVCN.TO
Avicanna
2 years ago
AVCN.TO
Avicanna
2 years ago
AVCN.TO
Avicanna
2 years ago
AVCN.TO
Avicanna
2 years ago

Currency in CAD
Earnings EstimateCurrent Qtr. (Mar 2022)Next Qtr. (Jun 2022)Current Year (2022)Next Year (2023)
No. of Analysts1111
Avg. Estimate-0.05-0.04-0.15-0.06
Low Estimate-0.05-0.04-0.15-0.06
High Estimate-0.05-0.04-0.15-0.06
Year Ago EPS-0.23-0.18-0.3-0.15
Revenue EstimateCurrent Qtr. (Mar 2022)Next Qtr. (Jun 2022)Current Year (2022)Next Year (2023)
No. of Analysts1111
Avg. Estimate1.7M2.1M9.1M15M
Low Estimate1.7M2.1M9.1M15M
High Estimate1.7M2.1M9.1M15M
Year Ago Sales271k792k3.27M9.1M
Sales Growth (year/est)527.30%165.20%178.40%64.80%
Earnings History2020-06-292020-12-302021-03-302021-12-30
EPS Est.-0.26-0.08-0.04-0.06
EPS Actual-0.23-0.18-0.14-0.18
Difference0.03-0.1-0.1-0.12
Surprise %11.50%-125.00%-250.00%-200.00%
EPS TrendCurrent Qtr. (Mar 2022)Next Qtr. (Jun 2022)Current Year (2022)Next Year (2023)
Current Estimate-0.05-0.04-0.15-0.06
7 Days Ago-0.05-0.04-0.15-0.06
30 Days Ago-0.05-0.04-0.15-0.06
60 Days Ago-0.05-0.04-0.15-0.06
90 Days Ago-0.05-0.04-0.15-0.06
EPS RevisionsCurrent Qtr. (Mar 2022)Next Qtr. (Jun 2022)Current Year (2022)Next Year (2023)
Up Last 7 DaysN/AN/AN/AN/A
Up Last 30 DaysN/AN/AN/AN/A
Down Last 7 DaysN/AN/AN/AN/A
Down Last 30 DaysN/AN/AN/AN/A
Growth EstimatesAVCN.TOIndustrySector(s)S&P 500
Current Qtr.78.30%N/AN/AN/A
Next Qtr.77.80%N/AN/AN/A
Current Year50.00%N/AN/AN/A
Next Year60.00%N/AN/AN/A
Next 5 Years (per annum)N/AN/AN/AN/A
Past 5 Years (per annum)N/AN/AN/AN/A


Insiders transactions are updated every hour.

Major Holders

Currency in CAD
Breakdown
23.93%% of Shares Held by All Insider
0.00%% of Shares Held by Institutions
0.00%% of Float Held by Institutions
0Number of Institutions Holding Shares
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by Avicanna Inc.


Avicanna Sells Stake in Majority-Owned Colombian Subsidiary Sativa Nativa

Avicanna Sells Stake in Majority-Owned Colombian Subsidiary Sativa Nativa

TORONTO, June 24, 2022 -- Avicanna Inc. ("Avicanna" or the "Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products is pleased to announce the sale of its stake in Sativa Nativa S.A.S. (“Sativa Nativa”), which was... Read More...
Avicanna's Subsidiary Santa Marta Golden Hemp Completes First Commercial Export of Feminized Cannabis Seeds to Lesotho

Avicanna’s Subsidiary Santa Marta Golden Hemp Completes First Commercial Export of Feminized Cannabis Seeds to Lesotho

This export marks the 16th international market entry for Avicanna and the first export of proprietary genetics into Africa. NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. TORONTO, June 09, 2022 -- Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopha... Read More...
Avicanna Subsidiary Santa Marta Golden Hemp S.A.S. Completes First Commercial Export of Aureus™ Branded THC and CBD Extracts to Portugal

Avicanna Subsidiary Santa Marta Golden Hemp S.A.S. Completes First Commercial Export of Aureus™ Branded THC and CBD Extracts to Portugal

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. TORONTO, May 24, 2022 -- Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based product... Read More...
Avicanna Reports Q1 2022 Financial Statement and Management Change

Avicanna Reports Q1 2022 Financial Statement and Management Change

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, May 12, 2022 -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, internati... Read More...
Avicanna Announces Closing of Strategic Private Placement

Avicanna Announces Closing of Strategic Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, May 06, 2022 -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, internati... Read More...
Avicanna Expands RHO PhytoTM Formulary with the Introduction of Cannabigerol (CBG) Products into the Canadian Market

Avicanna Expands RHO PhytoTM Formulary with the Introduction of Cannabigerol (CBG) Products into the Canadian Market

Avicanna introduces the rare cannabinoid CBG into its RHO Phyto product formulary which includes oral, sublingual, and transdermal formulations RHO Phyto CBG products will be made available through various medical and adult-use channels across Canada by Q3 2022 TORONTO, April 28, 2022 -- Avicanna Inc. (“Avicanna” or the “Company“) (TSX: A... Read More...
Avicanna Expands its Derma-Cosmetics Brand Pura H&W™ into the European Union through a Partnership with Bio-Gate AG

Avicanna Expands its Derma-Cosmetics Brand Pura H&W™ into the European Union through a Partnership with Bio-Gate AG

The exclusive distribution agreement includes 5 SKUs from Pura H&W’s evidence-based derma-cosmetics portfolio The products will be commercialized through Bio-Gate’s existing distribution channels with initial launches planned for Germany, Austria, and Switzerland in 2022 TORONTO, April 05, 2022 -- Avicanna Inc. (“Avicanna” or the “Com... Read More...
Avicanna Announces Filing of Annual Financial Statements for Year Ended December 31, 2021

Avicanna Announces Filing of Annual Financial Statements for Year Ended December 31, 2021

$3.3M in revenue representing 108% Y-Y growth, significant growth in finished product sales Total of 4 brands, 16 SKU’s and 35 “cannabis 2.0” listings across medical and retail channels in Canada Expansion of international footprint with entrance into Avicanna’s 14th international market TORONTO, March 31, 2022 -- Avicanna Inc. (“Avican... Read More...
Avicanna Enters into a Strategic Partnership with Tetra Bio-Pharma

Avicanna Enters into a Strategic Partnership with Tetra Bio-Pharma

TORONTO, Feb. 14, 2022 -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), an innovative, commercial-stage, and international biopharmaceutical company focused on the development, advancement, and commercialization of evidence-based, cannabinoid-based products, is pleased to announce that it has executed ... Read More...
Avicanna Provides Q4-2021 Results and Corporate Highlights as well as Fiscal 2022 Guidance

Avicanna Provides Q4-2021 Results and Corporate Highlights as well as Fiscal 2022 Guidance

TORONTO, Feb. 02, 2022 -- Avicanna Inc. (“Avicanna” or the “Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), an innovative, commercial-stage, and international biopharmaceutical company focused on the development, advancement, and commercialization of evidence-based, cannabinoid-based products, is pleased to provide fourth quarter 2021 r... Read More...
Avicanna Announces Closing of Non-Brokered Private Placement of Convertible Debenture Units

Avicanna Announces Closing of Non-Brokered Private Placement of Convertible Debenture Units

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, Jan. 28, 2022 -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), an innovative, commercial st... Read More...
Avicanna Enters Master Supply Agreement with Chilean Pharmaceutical Pioneer Knop Laboratorios S.A.

Avicanna Enters Master Supply Agreement with Chilean Pharmaceutical Pioneer Knop Laboratorios S.A.

Expansion and fortification of relationship since 2020 with established pharmaceutical company in Chile Supply of Avicanna’s active pharmaceutical ingredients for existing commercial and pipeline of pharmaceutical products in South America TORONTO, Jan. 14, 2022 -- Avicanna Inc. (“Avicanna” or the “Company“) (TSX: AVCN) (OTCQX: AVCNF) (FS... Read More...
Avicanna Announces the Appointment of Stephen Kim as Chief Legal Officer & General Counsel

Avicanna Announces the Appointment of Stephen Kim as Chief Legal Officer & General Counsel

TORONTO, Jan. 10, 2022 -- Avicanna USA Inc. together with Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of organic and sustainable plant-derived cannabinoid-based products, is pleased to announce the appointmen... Read More...
Avicanna Announces Changes to its Board of Directors

Avicanna Announces Changes to its Board of Directors

TORONTO, Jan. 04, 2022 -- Avicanna Inc. (“Avicanna” or the “Company“) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce the appointment of Eileen McCormack to, and the resignation of Setu Pur... Read More...
Avicanna Completes First Commercial Export of CBG Into the European Union

Avicanna Completes First Commercial Export of CBG Into the European Union

First commercial export of Cannabigerol (CBG), a rare cannabinoid, into Czech Republic This export represents the 14th international market entrance for Avicanna products TORONTO, Dec. 24, 2021 -- Avicanna Inc. (“Avicanna” or the “Company“) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manu... Read More...
Avicanna Launches its Clinically Backed CBD Derma-cosmetics Brand, Pura H&W, in the United States in Partnership with Red White and Bloom

Avicanna Launches its Clinically Backed CBD Derma-cosmetics Brand, Pura H&W, in the United States in Partnership with Red White and Bloom

The THC-Free, CBD derma-cosmetic brand is the first known CBD skincare line to be clinically tested and commercialized across four international markets The initial launch of Pura H&W will include seven SKUs of proprietary products that will be available through e-commerce as well as cannabis and non-cannabis specific retailers TORONT... Read More...
Avicanna and Harrington Wellness launch re+PLAY™ branded CBD topicals products in Canada

Avicanna and Harrington Wellness launch re+PLAY™ branded CBD topicals products in Canada

re+PLAY is a sports performance and recovery-focused brand founded by NBA veteran Al Harrington with and evidence-based CBD formulations developed in partnership with Avicanna Products will be available across adult use channels in Alberta and Ontario and medical channels in partnership with Medical Cannabis by Shoppers™ This marks the 4t... Read More...
Avicanna to Participate in the Lytham Partners Winter 2021 Investor Conference

Avicanna to Participate in the Lytham Partners Winter 2021 Investor Conference

TORONTO, Dec. 10, 2021 -- Avicanna Inc. ("Avicanna") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, announced today it will be participating in the Lytham Partners Winter 2021 Investor Conference taking place f... Read More...
Avicanna Files a Patent to Protect its Advanced Oral Cannabinoid Platform and its Applications for Neurological Diseases

Avicanna Files a Patent to Protect its Advanced Oral Cannabinoid Platform and its Applications for Neurological Diseases

Proprietary formulations include a range of liquids, capsules, powders, and controlled release tablets utilizing Avicanna’s self-emulsifying drug delivery systems (SEDDS) technology The advanced formulations offer enhanced stability, bioavailability and controlled release of cannabinoids including (CBD, THC, CBG, CBN and THCv) Avicanna i... Read More...
Avicanna Enters into an Intellectual Property Licensing and Distribution Agreement with Established Pharmaceutical Company in Argentina

Avicanna Enters into an Intellectual Property Licensing and Distribution Agreement with Established Pharmaceutical Company in Argentina

TORONTO, Nov. 30, 2021 -- Avicanna Inc. ("Avicanna") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, is pleased to announce that it has entered into a partnership with an established Argentine pharmaceutical com... Read More...
Avicanna Expands its Medical Cannabis Brand RHO Phyto into the Caribbean Region with Initial Export to Barbados

Avicanna Expands its Medical Cannabis Brand RHO Phyto into the Caribbean Region with Initial Export to Barbados

Starting with 3 SKUs, the advanced medical cannabis formulary will be available for the medical community and patients through prescriptionDistribution partnership with Bryden Stokes Limited includes initial focus on Barbados with plans to expand further into the Caribbean regionThird active country for RHO Phyto formulations and 13th int... Read More...
Avicanna Announces Filing of Interim Financial Statements for the Three-Month Period Ending September 30, 2021, Demonstrating Progressive Commercialization Results

Avicanna Announces Filing of Interim Financial Statements for the Three-Month Period Ending September 30, 2021, Demonstrating Progressive Commercialization Results

Record gross revenue of $1,007,033 through steady growth and progression of global commercializationDelivered a record number (27,041) of units of cannabis 2.0 products globally, an increase of 61% from Q225 listings of cannabis 2.0 products across adult use and medical channels in Canada.Expanded into and completed exports into the 12th ... Read More...
Avicanna Announces Resignation of Director

Avicanna Announces Resignation of Director

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, Nov. 11, 2021 -- Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company ... Read More...
Avicanna Inc. to Host Third Quarter 2021 Investor Conference Call on November 12 and Announces Warrant Repricing

Avicanna Inc. to Host Third Quarter 2021 Investor Conference Call on November 12 and Announces Warrant Repricing

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/ TORONTO, Nov. 08, 2021 -- Avicanna Inc. (“Avicanna” or the “Company“) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical compan... Read More...
Avicanna Announces Management Change

Avicanna Announces Management Change

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, Nov. 05, 2021 -- Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company ... Read More...
Avicanna Completes Commercial Export of CBD Isolate and CBD Full Spectrum Psychoactive Derivatives from Colombia to Chile

Avicanna Completes Commercial Export of CBD Isolate and CBD Full Spectrum Psychoactive Derivatives from Colombia to Chile

The Cannabis Derivatives are derived from Avicanna’s cultivation and extraction infrastructure in Santa Marta, Colombia designed to supply partner companies and the manufacture of Avicanna’s own finished products. TORONTO, Oct. 22, 2021 -- Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutic... Read More...
Avicanna Closes Non-Brokered Private Placement Raising $3.9 Million and Announces Warrant Repricing

Avicanna Closes Non-Brokered Private Placement Raising $3.9 Million and Announces Warrant Repricing

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, Oct. 19, 2021 -- Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company ... Read More...
Avicanna Completes First Commercial Export of Feminized Cannabis Seeds from Colombia to Peru and Argentina

Avicanna Completes First Commercial Export of Feminized Cannabis Seeds from Colombia to Peru and Argentina

This marks Avicanna’s first commercial exports of proprietary genetics in the form of feminized seeds into the Peruvian and the Argentine medical cannabis markets.Avicanna worked closely with the Colombian and Argentine ministries of agriculture to establish the phyto-sanitary requirements to allow for continuous supply to the emerging Ar... Read More...
Avicanna Files US Patent Application for a Novel Cannabinoid Formulation in Reducing Incidence of Seizures and Sudden Unexpected Death in Epilepsy

Avicanna Files US Patent Application for a Novel Cannabinoid Formulation in Reducing Incidence of Seizures and Sudden Unexpected Death in Epilepsy

Research findings originated from cannabinoid-based collaboration with leading epilepsy researcher, Dr. Peter Carlen, at UHN that is also supported by a Mitacs Accelerate program grant.Avicanna’s proprietary formulation showed promising pre-clinical results in reducing seizures and will be developed through the company’s pharmaceutical de... Read More...
Avicanna Completes Registration and Commercial Export of its Evidence-Based CBD Dermacosmetics Brand, Pura Earth, in Ecuador

Avicanna Completes Registration and Commercial Export of its Evidence-Based CBD Dermacosmetics Brand, Pura Earth, in Ecuador

Four SKUs of Pura Earth branded dermacosmetics have been successfully registered with ARCSA, imported into Ecuador, and will be distributed and commercialized through previously announced partnership with Spenta S.A.This marks the 12th country and market opening of Avicanna’s product offerings. /NOT FOR DISTRIBUTION TO UNITED STATES NEWS... Read More...
Avicanna Announces Revocation of Cease Trade Order

Avicanna Announces Revocation of Cease Trade Order

TORONTO, Sept. 13, 2021 -- Avicanna Inc. ("Avicanna" or the "Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that the failure-to-file cease trade order (the "CTO") issued by the On... Read More...
Avicanna Announces Filing of Interim Financial Statements for Period Ended June 30, 2021 and Provides Corporate Update

Avicanna Announces Filing of Interim Financial Statements for Period Ended June 30, 2021 and Provides Corporate Update

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/ TORONTO, Sept. 10, 2021 --  Avicanna Inc. ("Avicanna" or the "Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical compa... Read More...
Avicanna Announces Filing of Interim Financial Statements For Three Month Period Ended March 31, 2021

Avicanna Announces Filing of Interim Financial Statements For Three Month Period Ended March 31, 2021

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/ TORONTO, Sept. 07, 2021 -- Avicanna Inc. ("Avicanna" or the "Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical compan... Read More...
Avicanna Announces Filing of Annual Financial Statements For Year Ended December 31, 2020

Avicanna Announces Filing of Annual Financial Statements For Year Ended December 31, 2020

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/ TORONTO, Sept. 03, 2021 -- Avicanna Inc. ("Avicanna" or the "Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical compan... Read More...
Avicanna Completes First Commercial Export of Aureus Branded Full Spectrum Psychoactive CBD Cannabis Extracts to Brazil

Avicanna Completes First Commercial Export of Aureus Branded Full Spectrum Psychoactive CBD Cannabis Extracts to Brazil

This initial export to Brazil marks Avicanna’s first commercial export of psychoactive Cannabis Extracts into the emerging Brazilian medicinal cannabis market and the delivery of the initial purchase order from the previously announced three (3) year master supply agreement.This shipment also marks the 11th country to which SMGH has expor... Read More...
Avicanna Expands Sales of Pura Earth and RHO Phyto Branded Topicals into Alberta's Retail Channels

Avicanna Expands Sales of Pura Earth and RHO Phyto Branded Topicals into Alberta’s Retail Channels

Initial listings of topical SKUs include 3 Pura Earth branded facial topical products and 1 RHO Phyto branded Extra Strength Deep Tissue GelAvicanna’s leadership in the emerging category of topicals, with listings now in 5 provinces, is attributed to the proprietary functional formulations and clinical evidence behind the products /NOT F... Read More...
Avicanna Announces Closing of Secured Debt Financing

Avicanna Announces Closing of Secured Debt Financing

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/ TORONTO, Aug. 19, 2021 -- Avicanna Inc. (the “Company” or “Avicanna”) (TSX: AVCN) is pleased to announce closing of the previously anno... Read More...
Avicanna Enters Partnership with Heritage Cannabis Holdings Corp. to Commercialize Evidence-Based Topical Products through Heritage's Medical Cannabis Channels

Avicanna Enters Partnership with Heritage Cannabis Holdings Corp. to Commercialize Evidence-Based Topical Products through Heritage’s Medical Cannabis Channels

Exclusive licensing of certain of Avicanna’s advanced and evidence-based CBD topical products including its deep tissue and skin care formulations.Heritage to lead medical sales and commercialization across non-competing medical channels in Canada under the Opticann brand. /NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DI... Read More...
Avicanna Announces Partial Revocation of Cease Trade Order and Proposed Financing

Avicanna Announces Partial Revocation of Cease Trade Order and Proposed Financing

TORONTO, Aug. 03, 2021 -- Avicanna Inc. (the “Company” or “Avicanna”) (TSX: AVCN) announces that the Ontario Securities Commission ("OSC") has issued an order dated July 30, 2021 (the “Partial Revocation Order”) partially revoking the failure-to-file cease trade order issued against the Company on June 11, 2021 (the "FFCTO") for failing t... Read More...
Avicanna Completes First Commercial Export of Aureus™ Branded THC Active Pharmaceutical Ingredients to Peru

Avicanna Completes First Commercial Export of Aureus™ Branded THC Active Pharmaceutical Ingredients to Peru

Believed to be the first commercial export of psychoactive THC cannabis extract from Colombia to Peru.This marks Avicanna’s initial entrance into the emerging Peruvian cannabis market where the potential market opportunities also include its cosmetic, medical cannabis, and pharmaceutical products. /NOT FOR DISTRIBUTION TO UNITED STATES N... Read More...
Avicanna Completes First Commercial Export of Aureus™ Branded THC Extracts to Austria and Welcomes Colombian Government's Progressive New Regulation on Cannabis

Avicanna Completes First Commercial Export of Aureus™ Branded THC Extracts to Austria and Welcomes Colombian Government’s Progressive New Regulation on Cannabis

This initial export to Austria marks Avicanna’s first commercial export of psychoactive THC Cannabis Extracts into the emerging European medicinal cannabis market. The new decree by the Colombian government is designed to progress commercial initiatives related to the cannabis sector and fortify Colombia’s competitive advantages at a glob... Read More...
Avicanna Announces Change of Auditor

Avicanna Announces Change of Auditor

TORONTO, July 16, 2021 -- Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, announces the appointment of Kingston Ross Pasnak LLP (the “Successor Auditor”) as its independ... Read More...
Avicanna Executes Multi Year Agreement to Supply Brazilian Pharmaceutical Company with THC and CBD Cannabis Extracts

Avicanna Executes Multi Year Agreement to Supply Brazilian Pharmaceutical Company with THC and CBD Cannabis Extracts

Avicanna’s standardized CBD and THC Cannabis Extracts are to be utilized to produce a range of cannabis-derived products for the Brazilian market of 211 million people.Fulfillment of purchase orders based on preliminary forecasts for 2022 is expected to generate approximately CAD$4 million in revenue for Avicanna. /NOT FOR DISTRIBUTION TO... Read More...
Avicanna Financial Statement Update

Avicanna Financial Statement Update

TORONTO, June 30, 2021 -- Avicanna Inc. (the “Company” or “Avicanna”) (TSX: AVCN) announced today that the Company’s audit is ongoing and it expects to file the following periodic disclosure documents (collectively, the “Documents”) within the next sixty to seventy-five days: audited annual financial statements for the year ended December... Read More...
Avicanna and Bio-Gate Complete First Phase of Development on Cannabidiol (CBD) and MicroSilver BG™ Based Skin Care Products for Global Commercialization

Avicanna and Bio-Gate Complete First Phase of Development on Cannabidiol (CBD) and MicroSilver BG™ Based Skin Care Products for Global Commercialization

Initial development is part of a licensing and development agreement between the two companies to develop and deliver dermatology and cosmetic products.Combination of Avicanna’s intellectual property and Bio-Gate’s MicroSilver BG™ technology is aimed to target indications including eczema, acne, and atopic dermatitis. /NOT FOR DISTRIBUTIO... Read More...
Avicanna Announces Results of Annual General Meeting and Provides Corporate Update

Avicanna Announces Results of Annual General Meeting and Provides Corporate Update

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/ TORONTO, June 24, 2021 -- Avicanna Inc. (the “Company” or “Avicanna”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is pleased to announce that... Read More...
Avicanna Expands The Canadian RHO Phyto Product Offerings With The Addition Of THC-Free High CBD Oral And Sublingual Formulation Across Medical And Adult Use Channels

Avicanna Expands The Canadian RHO Phyto Product Offerings With The Addition Of THC-Free High CBD Oral And Sublingual Formulation Across Medical And Adult Use Channels

The two THC-Free RHO Phyto products will be available through the Medical Cannabis By ShoppersTM online portal and across specific adult use channels. Avicanna’s commercial products in Canada increase to 10 SKU’s where the CBD only oral products are targeted at patients, wellness focused consumers and new users who seek the benefits of CB... Read More...
Avicanna Announces Mailing of Management Information Circular and Proposed Board Changes

Avicanna Announces Mailing of Management Information Circular and Proposed Board Changes

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/ TORONTO, June 03, 2021 -- Avicanna Inc. (the “Company” or “Avicanna”) (TSX: AVCN) is announcing that it has commenced mailing its manag... Read More...
Avicanna's Evidence-Based and Dermatologist Tested CBD Derma-Cosmetic Brand Pura Earth™ to be Launched in Adult-Use and Medical Channels Across Canada in Q2 2021

Avicanna’s Evidence-Based and Dermatologist Tested CBD Derma-Cosmetic Brand Pura Earth™ to be Launched in Adult-Use and Medical Channels Across Canada in Q2 2021

The THC-Free, CBD derma-cosmetic brand is the first known CBD skincare line to be clinically tested and commercialized across cannabis channels nationwide in Canada. The initial launch of Pura Earth will include 3 products that will be available through Medical Cannabis by Shoppers™ online platform and across adult-use channels in Ontario... Read More...
Coming Soon.
IndexLast% Change
S&P 5003,911.74

3.06%Positive

Euro STOXX 503,533.17

2.82%Positive

FTSE 1007,208.81

2.68%Positive

Nikkei 22526,491.97

1.23%Positive


Delayed data (1h)
IndexLast% Change
S&P 5003,911.74

3.06%Positive

Euro STOXX 503,533.17

2.82%Positive

FTSE 1007,208.81

2.68%Positive

Nikkei 22526,491.97

1.23%Positive



Share this page